OR WAIT null SECS
May 13, 2015
Pall has agreed to be acquired by Danaher for $127.20 per share.
With acquisition of Oncaspar portfolio for leukemia from Sigma-Tau Finanziaria, Baxter BioScience adds an oncology infrastructure and biologic.
May 12, 2015
The agency publishes draft guidance answering industry questions about the Biologics Price Competition and Innovation Act.
May 07, 2015
The US Court of Appeals granted Amgen’s request to block Novartis’ Neupogen biosimilar, Zarxio, from the US market until the court resolves litigation between the two companies.
May 02, 2015
While the United States and Europe still dominate, CMOs and CROs based in emerging markets continue to capture market share.
The European Pharmacopoeia defines the format and content of monographs for biologicals to keep pace with recent approaches and meet the needs of its users.
April 28, 2015
FDA releases long-awaited guidance documents regarding the assessment of biosimilarity.
April 24, 2015
The agency has recommended granting marketing authorization for Opdivo.
April 23, 2015
Originator product manufacturers will have to update and improve their processing platforms to stay competitive with the biosimilars coming to market.
April 17, 2015
The acquisition expands Sartorius Stedim Biotech’s service portfolio.